Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Egyesült Államok1. fázis

Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC

A legfontosabb adatok

Ki végzi
Dana-Farber Cancer Institute
Hol
Boston (Egyesült Államok)Mind a 2 helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Fázis
1. fázis
Résztvevők
30 fő, tervezett
Kezdés
2027. ápr. 30.
Várható befejezés
2028. jún. 30.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • TNG462 vopimetostat
  • Lorlatinib
A regiszteradat frissítve
2026. november 16.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 31 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥ 18 years
  • Histologically or cytologically confirmed NSCLC harboring an ALK rearrangement, documented by an FDA/EMA-approved or validated local test
  • Confirmed MTAP loss, demonstrated by immunohistochemistry (IHC) as complete loss in the presence of a positive internal control, or homozygous deletion by next-generation sequencing (NGS) in a CLIA-/ISO-accredited laboratory. The Sponsor-Investigator will review molecular testing to confirm eligibility (central reading of the IHC sample and/or repeat MTAP staining on archival tissue; check of the NGS report). Cases with heterogenous MTAP loss in IHC defined as MTAP loss in at least 80% of the tumor cells but less than 100%, may be included with the permission of the Sponsor-Investigator and after central revision of the slides
  • Radiographic disease progression after at least one or more ALK TKIs, including prior lorlatinib therapy. Prior chemotherapy and prior neladalkib (NVL-655) are allowed
  • At least one measurable extracranial lesion according to RECIST v1.1
  • ECOG performance status 0-1 (Appendix A). ECOG performance status 2 may be allowed with the permission of the Sponsor-Investigator
  • Adequate organ and marrow function, defined as:; ANC ≥ 1.5 × 10⁹/L; Platelets ≥ 75 × 10⁹/L, without platelet transfusion within 7 days prior to screening hematology assessment; Hemoglobin > 8.5 g/dL without transfusion within 14 days prior to screening hematology assessment; AST/ALT ≤ 2.5 × ULN (≤ 5 × ULN with documented liver metastases); Total bilirubin ≤ 1.5 × ULN; Creatinine clearance ≥ 45 mL/min
  • Stable, previously treated brain metastases permitted if neurologically stable ≥ 2 weeks and on ≤ 10 mg prednisone equivalent. Untreated CNS metastases may be permitted with PI approval if: lesions are asymptomatic, ≤5 mm in size, no radiologic evidence of surrounding edema, and no current or anticipated need for corticosteroids
  • Life expectancy ≥ 12 weeks
  • Ability to swallow oral medication. TNG 462 tablets may be crushed and administered via NG-G tube if necessary, with written approval from Principal Investigator. Lorlatinib may not be crushed
  • Written informed consent obtained prior to study procedures
  • Participants must understand, sign and date the written informed consent form prior to any protocol-specific procedures performed. Participants should be able and willing to comply with study visits and procedures as per protocol

Ki nem vehet részt

  • Leptomeningeal carcinomatosis or spinal cord compression unless treated, clinically stable ≥ 4 weeks, and off steroids ≥ 14 days
  • History of myocardial infarction, unstable angina, coronary revascularization, stroke, or transient ischemic attack (TIA) within 6 months before C1D1
  • Interstitial lung disease, organizing pneumonia, or drug-induced pneumonitis, including prior lorlatinib-related pneumonitis, unless completely resolved
  • Active uncontrolled infection requiring intravenous therapy within 7 days before C1D1
  • Any other active malignancy within 2 years prior to enrollment, except adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, early-stage prostate cancer undergoing active surveillance, curatively treated thyroid cancer, early stage breast cancer or DCIS, or any in situ cancers that have been treated with curative intent
  • Has any of the following: prior history of drug-induced or toxic retinopathy, or optic neuropathy; uncontrolled glaucoma; pre-existing macular degeneration; ongoing Grade ≥3 retinopathy, optic neuropathy, or optic neuritis; or any other known active retinal pathology
  • History of seizure disorder requiring enzyme-inducing antiepileptic drugs that cannot be substituted
  • Symptomatic congestive heart failure (NYHA ≥ Class II) or uncontrolled hypertension despite optimal medical therapy
  • Known HBsAg-positive or HCV RNA-positive infection with detectable viral load. Participant on suppressive antiviral therapy with undetectable viremia are eligible
  • HIV infection with CD4 < 200/μL or on antiretrovirals that are strong CYP3A modulators
  • Clinically significant gastrointestinal disorder that may affect absorption of oral medications (e.g., malabsorption syndrome, chronic diarrhea, short-bowel syndrome)
  • Clinically significant neurocognitive disorder, mood alteration, or psychiatric illness (including major depression or psychosis) that, in the investigator's judgment, could be exacerbated by lorlatinib or impair adherence
  • Known hypersensitivity to TNG462, lorlatinib, or any of their excipients
  • 3.2.1 Prior treatment with a PRMT5 inhibitor, MAT2A inhibitor, or any investigational agent targeting the same pathway; 3.2.2 Prior treatment with lorlatinib resulting in discontinuation due to ≥ Grade 3 toxicity or with unresolved ≥ Grade 2 neurocognitive, pulmonary, or psychiatric adverse events at screening; 3.2.3 Ongoing or unresolved toxicity > Grade 1 from previous anticancer therapy (per CTCAE v5.0), except for the following: alopecia, endocrinopathies controlled by replacement therapy, or other protocol-allowed persistent Grade 2 toxicities (e.g., neuropathy) that, in the investigator's judgment, do not pose an unacceptable safety risk; 3.2.4 Major surgery within 4 weeks before first dose or incomplete recovery from surgery; 3.2.5 Radiotherapy within 2 weeks before C1D1 (≤ 1 week for palliative RT ≤ 2 Gy/fraction); prior cranial RT permitted if completed ≥ 2 weeks before C1D1 and participant neurologically stable; 3.2.6 Concomitant use of strong or moderate CYP3A inhibitors or inducers, CYP3A or P-gp substrates with a narrow therapeutic index (e.g., digoxin, cyclosporine), or OATP1B3 substrates with a narrow therapeutic index (e.g. rosuvastatin, methotrexate, sirolimus), that cannot be discontinued or replaced; 3.2.7 Use of medications known to prolong QTc > 480 ms that cannot be safely discontinued
  • Baseline QTc > 480 ms (Fridericia), PR > 220 ms, clinically significant atrioventricular (AV) block, or uncontrolled arrhythmia
  • Uncontrolled hyperlipidemia defined as fasting total cholesterol > 300 mg/dL or triglycerides > 300 mg/dL despite medical management
  • Pregnancy or breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 7 days before first dose and agree to use two highly effective contraceptive methods during treatment and for ≥ 6 months after the last dose. Male participants must use effective contraception for ≥ 3 months after the last dose
  • Any condition (medical, psychiatric, social, or laboratory abnormality) that, in the opinion of the investigator, may confound study results, increase risk, or interfere with study compliance
  • Participants who, in the investigator's or Sponsor-Investigator's judgment, are unable to comply with protocol requirements or whose participation would not be in their best interest may be excluded

Helyszínek itt: Egyesült Államok

  • Brigham and Women's HospitalBoston, Egyesült ÁllamokContact: Alice Shaw, MD, PhDToborzás még nem indult
  • Dana-Farber Cancer InstituteBoston, Egyesült ÁllamokContact: Alice Shaw, MD, PhDToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

TAP-ALK is a DF/HCC investigator-sponsored interventional study of TNG462 (vopimetostat) in combination with lorlatinib for participants with MTAP-deleted, ALK-rearranged non-small cell lung cancer (NSCLC) following progression on prior tyrosine kinase inhibitor (TKI) therapy. The study is being conducted under IND 183798 and plans to enroll 30 participants.

A vizsgálat csoportja

  • TNG462 plus LorlatinibA vizsgált kezelés

    Participants receive TNG462 once daily and lorlatinib once daily according to the study treatment plan and study calendar.

    Kezelés: TNG462 vopimetostat és Lorlatinib

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
TAP-ALK: A Phase I/II Study of TNG462 in Combination With Lorlatinib in MTAP-Deleted, ALK-Rearranged NSCLC Following Progression on Prior TKI Therapy
A regiszteradat frissítve
2026. november 16.